Treatment of rheumatoid arthritis - Does it affect society's cost for the disease?

British Journal of Rheumatology

Volumn 35, Issue 8, 1996, Pages 791-795

  Magnusson, S ^a  

^a SUNDSVALL HOSPITAL   (Sweden)

Author keywords

Costs to society; Rheumatoid arthritis; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; AURANOFIN; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BLOOD ANALYSIS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SOCIETY;

ADULT; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SWEDEN; TIME FACTORS; WORKERS' COMPENSATION;

EID: 0029765116     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Workshop. Pharmacological treatment in rheumatoid arthritis. The Medical Products Agency in Sweden, 1992:3.
2. Fehlauer CS, Carson CW, Cannon GW et al. Methotrexate therapy in rheumatoid arthritis: 2-year retrospective followup study. J Rheumatol 1989;16:307-12.
3. Rains CP, Noble S, Faulds D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995;50:137-56.
4. Itokazu M, Matsunaga T, Oshita Y. Efficacy and safety of auranofin in patients with active early rheumatoid arthritis. Clin Ther 1995;17:60-73.
5. Mackenzie AH, Scherbel AL. Chloroquine and hydroxychloroquine in rheumatological therapy. Clin Rheum Dis 1980;6:545-66.
6. Keysser M. Therapy of rheumatoid arthritis with azathioprine - results of an open long-term study of at least 4 years with 528 patients. Z Rheumatol 1993;52:133-7.
7. Vignos PH, Thomson HM, Katz S, Moskowitz RW, Fink S, Svec KH. Comprehensive care and psycho-social factors in rehabilitation in chronic rheumatoid arthritis: a controlled study. J Chron Dis 1972;25:457-67.
8. McDuffie FC. Morbidity impact of rheumatoid arthritis on society. Am J Med 1985;78:1-5.
9. Hertzman P. De reumatiska sjukdomarnas samhällsekonomiska konsekvenser. [Costs of rheumatic diseases in Sweden in 1975.] IHE Report 1972;2. Lund: The Swedish Institute for Health Economics, 1979.
10. Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid arthritis. PharmacoEconomics 1994;6:513-22.
11. Statens beredning for utvärdering av medicinsk metodik. (The Swedish Council on Technology Assessment in Health Care, Stockholm, Sweden.) Slaganfall. November 1992.
12. Prashker M, Meenan R. The total costs of drug therapy for rheumatoid arthritis. Arthritis Rheum 1995;38:318-25.
13. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol 1985;12:245-52.
14. Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis. Effects of disease, social and work factors. Ann Intern Med 1980;93:551-6.
15. Robinson HS. The cost of rehabilitation in rheumatic disease. J Chron Dis 1958;8:713-8.
16. Brooks RG. Cost-benefit analysis of patients treated at a rheumatism centre. Ann Rheum Dis 1969;28:655-61.